Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD) – A Prospective Comparative Randomized Trial

• Published in: Mædica Vol. 19; no. 1; pp. 9 - 16
• Main Authors: MANUC, Teodora, PREDA, Carmen Monica, ISTRATESCU, Doina, GHEORGHE, Liana, CERBAN, Razvan, ESTER, Carmen, STROIE, Tudor Gheorghe, ALECU, Raluca Ioana, CIUCIUREANU, Claudiu Mihai, MARIN, Alexandra Ioana, TUGUI, Letitia, TIERANU, Cristian, ANDREI, Sorin Lucian, DICULESCU, Mircea, MANUC, Mircea
• Format: Journal Article
• Language: English
• Published: Tarus Media 01.03.2024
• Subjects: Original Paper
• ISSN: 1841-9038; 2069-6116
• DOI: 10.26574/maedica.2023.19.1.9

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an entity with a growing incidence but only a few pharmacological options. In Romania, the prevalence of MASLD has been increasing, while that of viral hepatitis has been decreasing. The purpose of this study is to compare two supplements for the treatment of MASLD. Methods: Between January 2020 and May 2022, 90 patients with MASLD were randomized to receive either silymarin 150 mg b.i.d (45 subjects) or essential phospholipids (EPLs) 825 mg b.i.d. (45 subjects) for six months. All study participants received recommendations for lifestyle and diet modifications. Assessment of the severity of steatosis and liver fibrosis was performed using FibroScan® with controlled attenuated parameter (CAP) at the beginning and end of treatment. Results: A total of 68 patients completed the trial. The two groups were statistically comparable in terms of clinical, biological and FibroScanR parameters. Aspartate transferase (AST) decreased from a median of 40 to 28 IU/L in the EPL arm (compared to 25→¨25.5 IU/L in the silymarin arm) (p-value=0.11) and alanine transaminase (ALT) decreased from 46 to 37.5 IU/L (compared to 31→30 IU/L) (p-value = 0.38). Plasma cholesterol levels also decreased significantly in the EPL group (218→189.5 mg/dL) compared to the silymarin arm (217→209 mg/dL) (p = 0.01). At the end of treatment, liver stiffness decreased by 0.7 KPa (6.9→6.2 KPa) in the EPL group but increased by 2.3 KPa (7.2→9.5 KPa) in the silymarin group (p = 0.1). The reduction in hepatic steatosis was comparable between the two groups: it decreased by 5% of the initial value. Conclusion: In our study, a six-month treatment with EPLs was superior to silymarin in MASLD patients because it succeeded in improving both laboratory parameters and liver fibrosis, as estimated by FibroScan®.